NCT07673211Not yet recruiting
Circulating cfDNA and HPV as Prognostic Biomarkers for First-Line Recurrent Metastatic Cervical Cancer
A Prognostic Research on First-Line Recurrent and Metastatic Cervical Cancer Using Circulating Cell-Free DNA and Human Papillomavirus Detection
Source: ClinicalTrials.gov · Last updated 29 Jun 2026
Brief summary (registry, in English)
Primary Objective of this study: To investigate the correlation between longitudinal quantitative dynamics of circulating tumor DNA (ctDNA) and HPV-derived cell-free DNA (HPV cfDNA) in peripheral blood and clinical prognosis among patients with recurrent and metastatic cervical cancer who achieved complete response following standard first-line systemic therapy.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 60 (estimated)
- First submitted
- 23 Jun 2026
- Start date
- Jun 2026
- Primary completion date
- Dec 2028
- Lead sponsor
- Zhejiang Cancer Hospital
- Diseases
- Cervical cancer
- NCT number
- NCT07673211
What you commit to
- Study type: Observational
- Planned participants: 60
- From Jun 2026 to the primary completion date, Dec 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Severe concomitant diseases, including: cardiovascular diseases (e.g., uncontrolled heart failure, unstable angina, etc.); pulmonary diseases (e.g., severe chronic obstructive pulmonary disease, interstitial pneumonia and other conditions impairing respiratory function); hepatic and renal dysfunction (e.g., decompensated liver cirrhosis, severe renal failure requiring dialysis, etc.);
Other illness
- History of other malignant tumors within the past 2 years;
Other
- Pregnant or breastfeeding women;
- Refusal to sign informed consent;
- Refusal to undergo serial blood collection.
Who the study is looking for
- Histopathologically confirmed cervical squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma;
- Patients with first recurrent or metastatic cervical cancer (including primary stage IVB disease);
- Received standard first-line therapy (TP/TC regimen plus immunotherapy ± bevacizumab);
- Achieved complete response (CR) following standard first-line treatment;
- Archived pathological biopsy specimens of recurrent/metastatic lesions prior to treatment available in our hospital;
- Participated in clinical trials of pharmaceutical therapy for first-line recurrent/metastatic cervical cancer conducted at our institution;
- Voluntarily participates in this study and provides written informed consent;
- Agrees to serial peripheral blood collection at scheduled time points;
- Willing to complete scheduled follow-up visits;
- Aged ≥ 18 years old.
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.